Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial-Reference-Cited by-同舟云学术

Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

Published:2022-08 Issue:8 Volume:9 Page:e594-e604
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Cools Frank,Virdone Saverio,Sawhney Jitendra,Lopes Renato D,Jacobson Barry,Arcelus Juan I,Hobbs F D Richard,Gibbs Harry,Himmelreich Jelle C L,MacCallum Peter,Schellong Sebastian,Haas Sylvia,Turpie Alexander G G,Ageno Walter,Rocha Ana Thereza,Kayani Gloria,Pieper Karen,Kakkar Ajay K,Avhad Ajit,Antunes Murillo,Thereza Rocha Ana,Gonzales Lama Jesus,Abyankar Atul,Kormann Adrian Paulo Morales,Van Zyl Louis,Kaul Upendra,Adams Frances,Aloysius Ivan,Capehorn Matthew,Kumar Pradeep,Mahajan Rajesh

Publisher

Elsevier BV

Subject

Hematology

Reference27 articles.

1. Anticoagulation in COVID-19;Bradbury;Lancet,2022

2. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19;Lawler;N Engl J Med,2021

3. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19;Goligher;N Engl J Med,2021

4. Prevention of venous thromboembolism in surgical patients;Agnelli;Circulation,2004

5. ISTH interim guidance on recognition and management of coagulopathy in COVID-19;Thachil;J Thromb Haemost,2020

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Preventive and Therapeutic Effects of Acute and Severe Inflammatory Disorders with Heparin and Heparinoid;Biomolecules;2024-08-28

2. Effect of Apixaban on Clinical Outcomes in Outpatients With COVID-19: The APOLLO Randomized Clinical Trial;Circulation;2024-07-02

3. Long-term course of ambulatory patients with COVID-19 initially treated with enoxaparin vs no anticoagulation: final analysis of the OVID (enoxaparin for outpatients with COVID-19) randomized trial;Research and Practice in Thrombosis and Haemostasis;2024-07

4. Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis;Thrombosis Research;2024-06

5. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19;Journal of Thrombosis and Haemostasis;2024-06